Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Lumosa Therapeutics Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 7, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	31,755	42,224	11,268	6,425	6,117	5,194
Market Cap Growth	-39.74%	274.74%	75.37%	5.04%	17.77%	28.50%
Enterprise Value	30,752	41,699	10,380	5,254	4,757	4,625
Last Close Price	188.50	250.00	68.15	39.31	40.16	35.03
PE Ratio	-	-	-	-	63.75	-
PS Ratio	852.46	1078.41	197.97	241.17	352.32	239.89
PB Ratio	19.49	21.91	7.89	3.85	2.89	3.28
P/TBV Ratio	19.65	22.09	8.05	4.01	2.95	3.68
EV/Sales Ratio	-	1065.00	182.37	197.19	273.96	213.59
Debt / Equity Ratio	0.01	0.00	0.01	0.00	0.01	0.01
Asset Turnover	0.02	0.02	0.03	0.01	0.01	0.01
Inventory Turnover	0.19	0.21	0.14	0.13	0.13	0.31
Quick Ratio	8.68	6.92	3.98	5.65	6.60	6.83
Current Ratio	10.00	7.64	4.76	6.44	7.23	7.07
Return on Equity (ROE)	-42.38%	-26.03%	-16.16%	-26.63%	5.18%	-24.54%
Return on Assets (ROA)	-15.70%	-11.78%	-13.26%	-9.03%	-13.01%	-13.73%
Return on Capital (ROIC)	-17.29%	-13.22%	-15.07%	-10.05%	-14.42%	-16.07%
Earnings Yield	-1.98%	-1.01%	-2.11%	-7.70%	1.57%	-6.21%
FCF Yield	-1.32%	-0.70%	-3.04%	-4.71%	-7.40%	-2.50%
Buyback Yield / Dilution	-1.84%	-0.64%	-0.03%	-7.61%	-24.92%	-3.01%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.